CompletedPhase 1psilocybin
PsilOCD: A Pharmacological-Challenge Feasibility Study
Sponsored by Imperial College London
NCT ID
NCT06258031
Target Enrollment
19 participants
Start Date
2022-10-28
Est. Completion
2024-07-24
About This Study
The purpose of this study is to assess the impact of psilocybin on cognitive inflexibility and neural plasticity in a cohort of people with obsessive-compulsive disorder (OCD).
Conditions Studied
Interventions
- •Psilocybin (COMP360)
Eligibility
Age:20 Years - 65 Years
Healthy Volunteers:No
View full eligibility criteria
Key Inclusion Criteria: * Aged 20 to 65 years; * Any gender; * A primary diagnosis of OCD (based on the Mini-International Neuropsychiatric Interview (M.I.N.I.)); * Has met diagnostic criteria for OCD for at least 12 months; * Willing to comply with protocol and associated lifestyle restrictions; * Adequate understanding of the English language to give informed consent and participate in the study; * Participant can attend visits as an outpatient; * Comfortable using a computer, access to internet from home, and willing to participate in some of the study visits via video-link. Key Exclusion Criteria: * Current or past history of dependent (according to ICD10 criteria) substance use (not including nicotine and/or caffeine), Tourette's syndrome, autism spectrum disorder, epilepsy, organic mental disorder, or a personality disorder apart from obsessive-compulsive personality disorder; * Current or past history of psychosis or mania in themselves or a first-degree relative; * Unstable physical health; * Significantly abnormal clinical test result; * Heavy smoker, or unable to attend the dosing days (including the subsequent recovery part) without a smoking break; * Unwillingness to allow their GP or mental health practitioners to be informed of their participation (or, to allow study team access to Summary Care Record).
Study Locations (1)
CIPPRes Clinic
London, United Kingdom